The multiple you read about in the trade press is not your multiple. Here is the number that applies to a brand doing $1M to $15M, and what moves it.
By Gerry Morton, Founder & CEO, NutriScience
Capstone Partners put the average vitamins and supplements M&A multiple at 10.7x EV/EBITDA across 2024 and 2025 year to date, ahead of the broader consumer sector at 9.7x. Seventy deals closed in the category in 2025 year to date, up from 59 the year before. Strategic buyers took 80% of them.
If you own a supplement brand, 10.7x is the number that sticks in your head. It is almost certainly not your number.
Multiples move with size, and they move hard. GF Data’s Q3 2025 figures for the lower middle market:
The 10.7x sector average is carried by deals five to twenty times the size of yours. A brand throwing off $2M of EBITDA is not in a 10x conversation. It is in a 5.5x to 6.5x conversation.
Take a brand doing $8M of revenue at a 25% EBITDA margin. That is $2M of EBITDA.
At 5.5x it sells for $11M. At 6.5x it sells for $13M. One turn of EBITDA is $2M, which is more than most founders pull out of the business in three years. And that turn is decided almost entirely by things you control.
Four things raise the number, in rough order of how much they matter:
Three things lower it: heavy Amazon dependence, unsupported label claims, and aging inventory nobody has taken a write-down on.
Founders with thin EBITDA often ask to be valued on revenue instead. Buyers do it too, at roughly 1x to 2x for a brand with real repeat purchase and clean margins. Be careful what you are asking for. If your EBITDA is thin because the business is subscale, a revenue multiple flatters you. If it is thin because you are reinvesting hard into a business with 70% gross margins and a growing subscription base, the revenue multiple is the honest one and you should push for it.
The multiple is set by the market. The EBITDA is set by you, and it is the bigger lever. Moving from a 20% to a 25% EBITDA margin on $8M of revenue adds $400K of EBITDA. At 6x, that is $2.4M of enterprise value, from margin work you would want to do anyway.
Founders spend their energy negotiating the multiple in the last three weeks. The money is in the eighteen months before that.
10.7x EV/EBITDA, average for vitamins and supplements M&A across 2024 and 2025 year to date. Carried by deals far larger than yours.
Closer to 5.5x at $1M to $5M of enterprise value, and 6.4x at $10M to $25M. The size gradient is steeper than most founders expect.
Five points of EBITDA margin on $8M of revenue is $400K. At 6x that is $2.4M of enterprise value, from work worth doing regardless.
Send us a note with your revenue, margin and channel mix and we will tell you honestly where we think you would price. No NDA needed for that conversation.